试验注册
PM54 联合细胞毒及靶向药物治疗晚期恶性肿瘤的 1/2 期研究
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
作者：PharmaMar
ClinicalTrials.gov · 2026年9月24日 · PharmaMar
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors. The study will also assess the antitumor activity of PM54 in combination with cytotoxic and targeted anticancer agents in terms of objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Conditions: Advanced Solid Tumor
Interventions: drug: PM54; drug: Irinotecan; drug: Doxorubicin
Phase: Phase 1, Phase 2
Enrollment: 231 (estimated)
Sponsor: PharmaMar (industry)
Countries: United States, France, Germany, Portugal
Status: not yet recruiting
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。